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Abstract: More than half of patients receiving prescription medicine for cancer pain have been 
reported to experience inadequate pain relief or breakthrough pain. Buccal administration can 
deliver lipophilic opioids rapidly to the systemic circulation through the buccal mucosa, limiting 
gastrointestinal motility and first-pass metabolism. This review updates the safety and efficacy 
of fentanyl buccal soluble film (FBSF) in patients with cancer pain. Literature was identified 
through searches of Medline (PubMed). Search terms included combinations of the following: 
cancer pain, fentanyl, fentanyl buccal soluble film, pharmacology, kinetics, safety, efficacy 
and toxicity. FBSF is an oral transmucosal form of fentanyl citrate developed as a treatment 
of breakthrough pain in opioid-tolerant patients with cancer. Studies have shown that it is well 
tolerated in the oral cavity, with adequate bioavailability and safety in cancer patients. Further 
studies are warranted to evaluate, in comparison with other short-acting opioids, its efficacy in 
the management of breakthrough cancer pain, its addictive potential and its economic impact 
in cancer patients.
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Introduction
Pain is a common symptom in cancer patients.1,2 It may be poorly controlled because 
it is underreported or patients may have problems with communication or cognition, 
and physicians may undertreat it due to both inherent biases and concerns about use of 
medications in cancer patients due to the presence of comorbid diseases, and increased 
risk of adverse drug reactions.3–6 Cancer pain management is truly a public health and 
quality-of-care issue. Pain in cancer patients is not yet treated effectively.1–4,7,8
Pain related to cancer is often characterized by two components: first, persistent 
pain, for which the treatment is long-acting opioid products; second, “breakthrough 
pain”. Breakthrough pain is defined as “the transient exacerbation of pain occurring in 
a patient with otherwise controlled persistent pain”,2 and is a common and distressful 
symptom. It has been reported in 64.8% of patients with cancer pain.9 Breakthrough 
pain was associated with higher pain scores and functional impairment.9
Cancer patients who experience pain with multiple distressing symptoms benefit 
from an interdisciplinary evaluation and management of these symptoms with the goal 
of maximizing their quality of life. Breakthrough pain episodes are treated with oral 
short-acting opioids such as hydromorphone, morphine, and oxycodone.2,10 Patients 
with cancer might experience inadequate pain relief most of the time. Breivik et al 
observed that 58% of cancer patients with breakthrough pain reported inadequate pain 
relief at all times.11 Consequently, the “ultrarapid”-acting opioids are indicated for this Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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type of pain. Specifically, with the transmucosal formulation 
of fentanyl the absorption through the oral mucosa from 
either the buccal cavity or sublingually is more rapid than 
oral absorption.2 Other benefits of oral transmucosal delivery 
include better tolerance in patients with dysphagia, nausea 
or vomiting,12 and minimization of first-pass metabolism.2,12 
Fentanyl is a potent opioid analgesic that is well absorbed via 
the oral mucosa.12–14 Various formulations are approved by 
regulatory authorities. The most recent product approved 
by the US Food and Drug Administration is fentanyl buccal 
soluble film (FBSF). This review provides the clinician with 
an update on the current role of FBSF, and its efficacy and 
safety in the management of cancer patients with pain.
Method
Literature was identified through searches of Medline 
(PubMed). A bibliographical review of articles identified by 
these searches was also performed. Search terms included 
combinations of the following: cancer pain, fentanyl, fentanyl 
buccal soluble film, pharmacology, kinetics, and toxicity. 
All clinical trials, retrospective studies, and case reports 
relevant to FBSF and published in English were identified. 
Each was reviewed for data on the clinical pharmacology 
and safety of FBSF administration. Data from these studies 
and information from review articles and pharmaceutical 
prescribing information were included in this review.
Fentanyl
Fentanyl is a mu-opioid receptor agonist, which acts as a pure 
agonist.13 It is a highly lipophilic compound that is freely 
soluble in organic solvents and sparingly soluble in water.15 
In its structure, fentanyl has a piperidine ring which plays an 
important role in its efficacy. The piperidine ring facilitates 
docking with the mu-opioid receptor.16 The association with 
the mu-opioid receptor is rapid (t½: 2.5 minutes). Fentanyl 
is more potent than morphine as evidenced by its Ki of 
2.9 ± 0.2 vs morphine’s Ki of 15.13 It has been described that 
fentanyl can interact with serotonin receptors as evidenced 
by its decreased analgesic effect when combined with 5-HT1A 
receptor antagonists.17 Fentanyl has high protein-binding 
ability and low water solubility. It has a high volume of 
distribution and a high molecular weight, and thus is not 
dialyzable.18 Fentanyl is mainly metabolized by N-dealky-
lation to norfentanyl (4-N-[N-propionylanilino] piperidine) 
and hydroxyfentanyl, which are present in plasma and urine.19 
There is minimal fecal excretion and it is mostly excreted by 
the kidneys.18,19 Cytochrome P450 isoforms, found in the small 
bowel, can produce first-pass metabolism of fentanyl when 
administered by the oral route.19 The activity of cytochrome 
P450 3A4, the main isoform responsible for N-dealkylation 
of fentanyl,19 is inhibited by macrolides, antifungal agents, 
antidepressants (sertraline, fluoxetine, fluvoxamine), oral 
contraceptives, omeprazole, antiviral agents, valproic acid and 
cimetidine. When fentanyl is combined with these medica-
tions, the duration of the effect is prolonged and elimination 
slowed. In contrast, antiretroviral medications and rifampin 
induce cytochrome P450 3A4 activity, reducing the analgesic 
effect of fentanyl.20,21 Fentanyl is compatible with dexametha-
sone, hyoscine butylbromide, levopromazine, haloperidol, 
ondansetron and midazolam.13
Fentanyl can be administered transdermally, intravenously, 
subcutaneously, transmucosally, and sublingually.13,14 Several 
fentanyl formulations are approved. Oral transmucosal fenta-
nyl citrate (OTFC) is a buccal formulation that is composed 
of a fentanyl lozenge on a stick that requires the patient to 
continuously roll a lollipop in the inner portion of their cheek. 
This form of administration and the formulation’s high sugar 
content can provide a suboptimal therapy for some patients.2 
Another buccal formulation is fentanyl buccal tablet (FBT), 
which has been approved in United States and Europe. This 
formulation acts through an effervescence reaction that 
enhances fentanyl absorption through the buccal mucosa. 
This effervescent buccal tablet can be absorbed twice as 
fast as when the drug is swallowed or as the fentanyl lol-
lipop.22–26 The most recent formulation of fentanyl that has 
been approved for the treatment of breakthrough pain in 
cancer patients is FBSF.
Fentanyl buccal soluble film
FBSF is an oral transmucosal form of fentanyl citrate. It has a 
BioErodible MucoAdhesive (BEMA®; BioDelivery Sciences, 
Inc., Raleigh, NC) delivery technology.14,27–29 This technology 
consists of two different layers made of water-soluble poly-
meric films, one bioadhesive layer and one inactive layer. The 
bioadhesive layer contains fentanyl citrate that adheres within 
seconds of making contact with the moist buccal mucosa. The 
inactive layer isolates the bioadhesive layer from the buccal 
cavity, minimizing the amount of fentanyl that is swallowed 
and facilitating delivery directly to the buccal mucosa.27–29 
Once applied FBSF starts to dissolve in minutes and is com-
pletely dissolved within 15 to 30 minutes without patient 
effort. It requires a minimal quantity of saliva. Delivered by 
this system, the proportion of the fentanyl dose that under-
goes transmucosal absorption is approximately 50% and the 
absolute bioavailability is approximately 71%29–31 (Table 1). 
In a randomized, open-label trial, 12 healthy subjects received Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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single doses of three FBSF formulations (pH 6, pH 7.25, 
and pH 8.5) and OTFC, with concurrent naltrexone. The study 
demonstrated that, of these three formulations, the pH 7.25 
FBSF formulation reached peak plasma fentanyl concentra-
tion (Cmax) fastest and had the highest Cmax value and the great-
est area under the curve concentration. Compared with OTFC, 
peak plasma fentanyl concentrations with pH 7.25 FBSF were 
significantly higher (mean Cmax 1.67 vs 1.03 ng/mL).28 There is 
a direct relationship between the surface area of the dose unit 
and the dose of fentanyl combined with the mucosa contact 
time that results in consistent plasma concentrations when 
equivalent doses are delivered by single or multiple dosage 
units.30 Consequently, the absorption surface area with a single 
800-µg dose is exactly the same as with four individual 200-µg 
films.29 Rauck et al in a multicenter, randomized, double-blind 
placebo-controlled, multiple-crossover study, with opioid-
tolerant adult patients with chronic cancer pain experiencing 
one to four  daily episodes of breakthrough pain, showed that 
FBSF is an effective option for control of breakthrough pain in 
patients receiving ongoing opioid therapy.14 This efficacy was 
evidenced by a greater number of the sum of pain intensity 
difference at 30 minutes postdose FBSF than placebo. FBSF 
was well tolerated in the oral cavity, with no treatment-related 
oral adverse effects.14 At this time no other study has compared 
the efficacy of FBSF against other short-acting opioids in 
cancer patients with pain.
The recommended starting dose of FBSF, regardless of 
prior therapy, is 200 µg per episode. The dose can be increased 
by 200 µg using 200-µg films in different areas of the mouth. 
If the pain persists after a 800-µg dose, a single 1200-µg film 
could be prescribed for the next episode.31 Single doses should 
be separated by at least 2 hours. It has been recommended that 
no more than four doses should be given per day. Doses higher 
than 1200 µg per episode are not recommended.31
Adverse events with FBSF are mainly gastrointestinal 
(nausea, vomiting, constipation) and central nervous sys-
tem disorders (dizziness, headaches). No changes have 
been reported in vital signs, electrocardiograms, physical 
examinations, or clinical laboratory tests.28 It is classified 
as category C (risk cannot be ruled out) for use during 
pregnancy.31
Conclusion
FBSF is an effective option for control of breakthrough pain 
in cancer patients receiving ongoing opioid therapy. It has 
adequate bioavailability and tolerability. Further studies are 
warranted to evaluate, in comparison with other short-acting 
opioids, its efficacy in the management of breakthrough 
cancer pain, its addictive potential and its economic impact 
in cancer patients.
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